Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding
- 1 June 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 31 (6), 1239-1245
- https://doi.org/10.1053/jhep.2000.8106
Abstract
The aim of this study was to test the effectiveness of isosorbide-5-mononitrate (IM) as an adjunct to propranolol (PR) in the prevention of variceal rebleeding. Ninety-five cirrhotic patients with variceal bleeding were randomly assigned to treatment with PR + IM (46 patients) or PR alone (49 patients). Eighteen patients in the PR + IM group and 28 in the PR group had rebleeding during the 2 years after randomization. The actuarial probability of rebleeding 2 years after randomization was lower in the PR + IM group (40.4% vs. 57.4%) but the difference was not significant (P = .09). However, the decrease in the risk of rebleeding reached statistical significance after stratification according to age, i.e. less than 50 versus ≥50 years old, (P = .03) or by adding an additional year of follow-up (P = .05). No significant difference was found in rebleeding index and survival. The multivariate Cox analysis indicated first, that both treatment (P = .03) and age (P = .001) were factors predictive of rebleeding and second, that PR + MI reduced the risk of rebleeding by half (relative risk: 0.51, 95% confidence interval: 0.28-0.95). Seven patients in the PR + MI group and 1 patient in the PR group had to discontinue one of the drugs because of adverse events (P = .03). These results suggest that the addition of IM improves the efficacy of PR alone in the prevention of variceal rebleeding in cirrhotic patients. However no beneficial effects were observed on other parameters reflecting the efficacy of treatment.Keywords
This publication has 26 references indexed in Scilit:
- Beta–Adrenergic Antagonists in the Prevention of Gastrointestinal Rebleeding in Patients With Cirrhosis: A Meta–AnalysisHepatology, 1997
- Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosisThe Lancet, 1995
- The treatment of portal hypertension: A meta-analytic reviewHepatology, 1995
- Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhageGastroenterology, 1990
- Liver Function and Pharmacological Considerations in Pathogenesis and Treatment of Portal HypertensionHepatology, 1990
- Enhancement of Portal Pressure Reduction by the Association of Isosorbide–5–Mononitrate to Propranolol Administration in Patients With CirrhosisHepatology, 1990
- Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosisGastroenterology, 1989
- Survival and prognostic indicators in compensated and decompensated cirrhosisDigestive Diseases and Sciences, 1986
- Increased Portal Venous Resistance Hinders Portal Pressure Reduction During the Administration of β–Adrenergic Blocking Agents in A Portal Hypertensive ModelHepatology, 1985
- Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in CirrhosisHepatology, 1984